Phase II, open-label, uncontrolled, single-dose study to evaluate the safety, tolerability and pharmacokinetics, and the development of anti-drug antibodies to nirsevimab in immunocompromised children ≥24 months of age
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA AB
- Phase: II
- Execution start: 27/09/2021
- End of execution: 30/05/2023
- IP: JUAN LUIS SANTOS PEREZ